The forecasted data for the re-import of vaccines for human use to France exhibits a significant downward trend from 2024 onwards. The data predicts a stark decrease by 2028, with volume reducing from 870.39 kilograms in 2024 to a mere 34.07 kilograms in 2028. Year-on-year, this indicates substantial negative variation, highlighting the decreasing reliance on re-imports for vaccine supply.

Key points:

The volume in 2023 was higher than projected for subsequent years, indicating a shift in sourcing or supply strategy.
The compound annual growth rate (CAGR) over the next five years is expected to be deeply negative, pointing to a sustained decline.

Future trends to watch for:

Monitor changes in domestic vaccine production capabilities, which could be influencing this re-import decline.
Regulatory shifts or trade agreements impacting the import of vaccines to France could alter these projections.
Emergence of alternative vaccine technologies or suppliers that might affect import patterns.